iTeos Therapeutics, Inc. - ITOS STOCK NEWS

iTeos Therapeutics (Nasdaq: ITOS), a biopharmaceutical firm focused on immuno-oncology, announced that CEO Michel Detheux will present at the 41st Annual J.P. Morgan Conference in San Francisco on January 10, 2023, at 8:15 a.m. PST. A live webcast of the event will be accessible on the company's website, with an archived replay available for 30 days post-presentation. iTeos is known for its innovative therapies aimed at enhancing the immune response against cancer, including its lead programs, EOS-448 and inupadenant.

iTeos Therapeutics (Nasdaq: ITOS) announces that Dr. Michel Detheux, CEO, will speak at the Piper Sandler 34th Annual Healthcare Conference in New York City on November 29, 2022, at 4:30 p.m. ET. A live webcast will be available on the company's website, with an archived replay accessible for 30 days post-event. iTeos specializes in immuno-oncology therapeutics, with programs like EOS-448, an anti-TIGIT antibody, and inupadenant, an adenosine A_2A receptor antagonist, currently advancing in clinical trials.

iTeos Therapeutics (ITOS) reported its Q3 2022 results, highlighting the initiation of a Phase 2 trial for anti-TIGIT monoclonal antibody EOS-448 combined with GSK’s Jemperli in first-line metastatic non-small cell lung cancer (NSCLC).

The company holds a strong cash position of $752 million, projected to sustain operations into 2026. R&D expenses rose to $23.9 million, largely due to heightened clinical activities. Notably, net income declined to $1 million, or $0.03 per share, compared to $69.6 million in the same quarter last year.

iTeos Therapeutics (ITOS) has initiated patient enrollment for two Phase 2 trials focusing on advanced cancer treatments. The trials evaluate the efficacy of EOS-448, an anti-TIGIT monoclonal antibody, in combination with GSK’s Jemperli for head and neck squamous cell carcinoma, and inupadenant, an adenosine A2A receptor antagonist, with chemotherapy for non-small cell lung cancer. As of June 30, 2022, the company reported a cash balance of $792 million, sufficient to support operations through 2026. Recent R&D expenses have risen to $26.9 million, reflecting increased clinical activities.

iTeos Therapeutics, Inc. (Nasdaq: ITOS) announced that its CEO, Michel Detheux, will participate in a panel discussion at the 2022 Wedbush PacGrow Healthcare Conference on August 9, 2022, at 8:00 a.m. ET. The topic will focus on opportunities and challenges in immuno-oncology.

A live webcast can be accessed on the company's website, with an archived replay available for 30 days post-event. iTeos is developing innovative immuno-oncology therapeutics, including the anti-TIGIT antibody EOS-448 and the adenosine A2A receptor antagonist inupadenant, aimed at enhancing the immune response against cancer.

Domain Therapeutics has appointed Dr. Xavier Leroy as Chief Scientific Officer (CSO), enhancing its leadership in immuno-oncology and GPCR programs. Previously serving as Chief Technology Officer, Dr. Leroy will now oversee research and the transition of the company to a clinical-stage biopharmaceutical entity. He highlights the opportunity to develop first-in-class candidates targeting new GPCRs. Dr. Leroy's extensive experience includes senior roles at Actelion Pharmaceuticals and significant contributions to raising $75M in funding for immuno-oncology projects.

iTeos Therapeutics (NASDAQ: ITOS) reported strong financial results for Q1 2022, achieving a net income of $69.6 million, or $1.96 per basic share. The company's cash reserves rose to $824 million, providing funding into 2026 for ongoing clinical trials. Key developments include the enrollment of patients in pivotal trials for EOS-448, an anti-TIGIT monoclonal antibody, and inupadenant, an A_2A receptor antagonist. Enhanced evidence of target engagement in tumors was presented at the AACR 2022, fueling optimism for their innovative cancer therapies.

iTeos Therapeutics has announced promising data on its anti-TIGIT antibody, EOS-448, presented at the AACR Annual Meeting 2022. The study revealed a decrease in TIGIT-positive cells in tumor biopsies, marking a significant treatment effect. Preclinical and clinical data demonstrate EOS-448's ability to reduce suppressive immune cell populations, indicating effective engagement of FcγR. These findings support ongoing clinical trials aimed at developing EOS-448 as a potent immuno-oncology therapy for patients with advanced cancers.

iTeos Therapeutics (ITOS) has made significant strides in its immuno-oncology pipeline, reporting a cash position of $848.5 million as of December 31, 2021, ensuring funding through 2026. The company is advancing its clinical trials for EOS-448, an anti-TIGIT antibody, and inupadenant, an A_2A receptor antagonist, in collaboration with GSK. Key initiatives include multiple registration-directed trials and triplet regimen studies, signaling robust clinical development plans. In 2021, iTeos reported a net income of $214.5 million, an improvement from a net loss the previous year.